Bone Morphogenetic Protein Market To Reach $459.9 Million By 2030

Bone Morphogenetic Protein Market Growth & Trends

The global bone morphogenetic protein market size is expected to reach USD 459.9 million by 2030, registering a CAGR of 4.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of spinal fusion, trauma, and small bone surgeries coupled with demand for faster bone recovery are the key drivers affirming growth of BMP market.

Low back pain and spinal disc dislocation are some of the most common occupational hazards. Over 75% of such disorders require spinal surgery after noninvasive treatment options are unable to provide any relief. Minimally invasive surgery, shorter hospital stays, and fast recovery are common demands observed among patients. BMP has gained high acceptance among orthopedic surgeons in recent years owing to its ability to cater above mentioned benefits

Sport-related injuries, growing geriatric population, and increasing awareness about osteoinduction products as an alternative to bone grafting are other drivers accentuating market growth. BMP has reported outstanding results over bone graft, such as lack of donor morbidity, extensive surgical procedure, higher recovery time, pain & numbness, and high cost.

 Request a free sample copy or view report summary: Bone Morphogenetic Protein Market Report

Bone Morphogenetic Protein Market Report Highlights

• rhBMP-2 and rhBMP-7 are the commercially available recombinant BMPs. rhBMP-2 is widely known for its high osteoinductive property for faster formation of bone and cartilage in bone fusion procedures.

• The rhBMP-2 segment held the largest market share of 73.9% in 2024 and is anticipated to grow at the higher CAGR from 2025 to 2030.

• rhBMP-7 segment is expected to grow at a moderate CAGR from 2025 to 2030. As healthcare professionals increasingly look for alternatives to autografts for bone repair, rhBMP-7's ability to promote healing without the complications associated with harvesting grafts could drive its adoption in clinical practice.

• The spinal fusion segment held the largest market share of 50.3% in 2024. The growth is attributed to the development of effective and efficient solutions, the increasing acceptance of these proteins over conventional treatments, and the ongoing research initiatives that strengthen their position in the market.

• North America held the largest market share of 49.6% in the global bone morphogenetic protein market in 2024. High number of orthopedic surgical procedures, and availability of favorable reimbursement policies are drivers that can be attributed to for largest share.

Bone Morphogenetic Protein Market Segmentation

Grand View Research has segmented the global bone morphogenetic protein market on the basis of on type, application, and region:

Bone Morphogenetic Protein Type Outlook (Revenue, USD Million, 2018 - 2030)

• rhBMP-2

• rhBMP-7

Bone Morphogenetic Protein Application Outlook (Revenue, USD Million, 2018 - 2030)

• Spinal Fusion

• Trauma

• Reconstruction

• Oral Maxillofacial

Bone Morphogenetic Protein Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Bone Morphogenetic Protein Market

• Medtronic plc

• Cellumed Co., Ltd.

• Cell Guidance Systems LLC

• Merck KGaA

• Prospec-Tany Technogene Ltd.

• Qkine Ltd.

• Bio-Techne.

• Thermo Fisher Scientific Inc.

• Proteintech Group, Inc.

• STEMCELL Technologies